Another ViewEPS of 12c matched estimates; sales of $35.6M missed estimates of $39.6M. EBITDA of $7.1M were 4% light of estimates. Sales rose 16%. Q4 EBITDA rose 79% year over year. GAAP net profit per share rose to 13c, from 9c. Per share free cash flow rose 32%. For the year, payout ratio was 54%, down from 62%. Despite the miss on estimates, we would still consider the growth decent here. The stock has done very well and might see some profit-taking, but still looks good for higher risk income at 17X earnings. (5iResearch)